Finding markers that indicate protection or risk from dengue vaccines and infections
Official title: Identification of serological markers of protection and risk for dengue vaccines and natural infection
Funded at Johns Hopkins University · NIH-11159254 · Data updated 2026-11-12
This study is looking at how our immune system reacts to dengue, whether from getting the virus or from vaccines, to find out what signs can show if someone might get severe dengue or be safe from it, and it involves checking blood samples from people over several years to see how these immune responses change.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $683,213 |
| NIH project number | 7R01AI175495-02 |
| Project ID | NIH-11159254 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have been vaccinated against dengue or have experienced dengue infections.
✕Less likely to help
Patients who have never been exposed to dengue or have not received any dengue vaccinations may not benefit from this research.
What this research studies
This research investigates how the immune response to dengue, both from natural infections and vaccinations, can be better understood. It focuses on identifying specific markers that indicate whether a person is at risk for severe dengue or is protected against it. By analyzing blood samples from individuals over several years, the study aims to characterize both neutralizing and non-neutralizing antibody responses, as well as cellular immune responses. This comprehensive approach will help clarify how these immune responses change over time and their relationship to disease risk.
Why it matters
Potential benefit: If successful, this research could lead to improved dengue vaccines and better strategies for managing dengue infections.
How similar studies have gone: Previous research has shown promise in understanding immune responses to dengue, but this study aims to provide deeper insights into both neutralizing and non-neutralizing responses, making it a novel approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Cummings, Derek a — Johns Hopkins University
- Study coordinator: Cummings, Derek a
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.